Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neurobiology of Aging

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neurobiolaging.2010.03.023PMID 20510480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plaque Deposition Dependent Decrease in 5-HT2A Serotonin Receptor in AβPPswe/PS1dE9 Amyloid Overexpressing Mice

  2010cited by this paper
• A Probabilistic Approach to Delineating Functional Brain Regions

  2009cited by this paper
• The personality trait openness is related to cerebral 5-HTT levels

  2009cited by this paper
• Altered Brain Serotonin Transporter and Associated Glucose Metabolism in Alzheimer Disease

  2009cited by this paper
• Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding.

  2009cited by this paper
• High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

  2009cited by this paper
• The evolution of the cognitive model of depression and its neurobiological correlates.

  2008cited by this paper
• A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease

  2008cited by this paper
• Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels.

  2008cited by this paper
• Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET

  2008cited by this paper
• Reduced 5-HT2A receptor binding in patients with mild cognitive impairment.

  2008cited by this paper
• A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.

  2007cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• Serotonergic vulnerability and depression: assumptions, experimental evidence and implications

  2007cited by this paper
• Immunodetection of the serotonin transporter protein is a more valid marker for serotonergic fibers than serotonin

  2006cited by this paper
• Serotonin and human cognitive performance.

  2006cited by this paper
• Serotonin 1A receptors in the living brain of Alzheimer's disease patients.

  2006cited by this paper
• Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients

  2006cited by this paper
• A study of the serotonin transporter in the prefrontal cortex in late‐life depression and Alzheimer's disease with and without depression

  2006cited by this paper
• MR-based automatic delineation of volumes of interest in human brain PET images using probability maps

  2005cited by this paper
• Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer’s disease

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation

  2004cited by this paper
• Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression.

  2004cited by this paper
• A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables

  2004cited by this paper
• Chemical identity of 5-HT2A receptor immunoreactive neurons of the rat septal complex and dorsal hippocampus.

  2004cited by this paper
• Hippocampal neurons in pre-clinical Alzheimer's disease.

  2004cited by this paper
• Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients

  2003cited by this paper
• Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease.

  2003cited by this paper
• Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach

  2003cited by this paper
• Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain

  2003cited by this paper
• Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex.

  2003cited by this paper
• Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

  2002cited by this paper
• PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.

  1999cited by this paper
• A multidisciplinary memory clinic in a neurological setting: diagnostic evaluation of 400 consecutive patients

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence.

  1998cited by this paper
• Quantitative Evaluation of 5-Hydroxytryptamine (Serotonin) Neuronal Release and Uptake: An Investigation of Extrasynaptic Transmission

  1998cited by this paper
• Tau in Alzheimer's disease.

  1998cited by this paper
• The prevalence, associations and symptoms of depression amongst dementia sufferers.

  1996cited by this paper
• Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

  1996cited by this paper
• Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus.

  1995cited by this paper
• Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus

  1995cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type.

  1994cited by this paper
• Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease.

  1994cited by this paper
• Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.

  1993cited by this paper
• Cell loss in the nucleus raphes dorsalis in Alzheimer's disease.

  1992cited by this paper
• Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.

  1991cited by this paper
• Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.

  1989cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Journal of Cerebral Blood Flow and Metabolism Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: Mri-based Correction for Partial Volume Effects

  year unknowncited by this paper

• The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease

  2025cites this paper
• Tracking Neural Deterioration in proNGF-Overexpressing Mice: Hippocampal Serotonergic Dysfunction and Synaptic Loss Drive Neurodegeneration

  2025cites this paper
• Monoamine alterations in Alzheimer’s disease and their implications in comorbid neuropsychiatric symptoms

  2024cites this paper
• Multimodal brain age prediction using machine learning: combining structural MRI and 5-HT2AR PET-derived features

  2024cites this paper
• Serotonin receptors - a potential target for the treatment of Alzheimer’s disease

  2023cites this paper
• The association between brain serotonin transporter binding and impulsivity and aggression in healthy individuals.

  2023cites this paper
• Serotonin Receptors as a Potential Target in the Treatment of Alzheimer’s Disease

  2023cites this paper
• Genetic contributions to brain serotonin transporter levels in healthy adults

  2023cites this paper
• Oligonol ameliorates liver function and brain function in the 5 × FAD mouse model: transcriptional and cellular analysis.

  2023cites this paper
• Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer’s Disease

  2022cites this paper
• State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities.

  2022cites this paper
• Radiotracers for the Central Serotoninergic System

  2022cites this paper
• Understanding How Physical Exercise Improves Alzheimer’s Disease: Cholinergic and Monoaminergic Systems

  2022cites this paper
• PET Agents in Dementia: An Overview.

  2021cites this paper
• Measurement of changes in endogenous serotonin level by positron emission tomography with [18F]altanserin

  2021cites this paper
• New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids.

  2021cites this paper
• Alterations and interactions of subcortical modulatory systems in Alzheimer's disease.

  2021cites this paper
• Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics.

  2021cites this paper
• Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer’s Disease

  2021cites this paper
• Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease

  2021cites this paper
• Psychedelic‐inspired approaches for treating neurodegenerative disorders

  2021cites this paper
• Applications, Advances, and Limitations of Molecular Imaging of Brain Receptors

  2021cites this paper
• Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

  2021cites this paper
• Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide.

  2021cites this paper
• Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease

  2020cites this paper
• Common HTR2A variants and 5‐HTTLPR are not associated with human in vivo serotonin 2A receptor levels

  2020cites this paper
• Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders

  2020cites this paper
• The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions

  2019cites this paper
• Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres

  2019cites this paper
• Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer’s disease

  2019cites this paper
• AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems.

  2019cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

  2019cites this paper
• PET Imaging of the 5-HT 2A Receptor System: A Tool to Study the Receptor’s In Vivo Brain Function

  2018cites this paper
• Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients

  2018cites this paper
• Brain Circuits Regulated by the 5-HT 2A Receptor: Behavioural Consequences on Anxiety and Fear Memory

  2018cites this paper
• Cognitive Impairment and Dementias.

  2018cites this paper
• Does Dopamine Depletion Trigger a Spreader Lexical-Semantic Activation in Parkinson's Disease? Evidence from a Study Based on Word Fluency Tasks

  2017cites this paper
• Molecular imaging of serotonin degeneration in mild cognitive impairment.

  2017cites this paper
• Monoaminergic neuropathology in Alzheimer's disease

  2017cites this paper
• Astrocytic transporters in Alzheimer's disease.

  2017cites this paper
• Western diet and its effect on motivation, learning and memory

  2017cites this paper
• Alzheimer's Drug Discovery Maze: A Snap View of the Past Decade's Diverse Pharmacological Targets for the Disorder.

  2017cites this paper
• The Association between 5HT2A T102C and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease: A Meta-Analysis

  2017cites this paper
• The Center for Integrated Molecular Brain Imaging (Cimbi) database

  2016cites this paper
• Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

  2016cites this paper
• G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases.

  2016cites this paper
• 5-HT2A Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study

  2016cites this paper
• Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases

  2016cites this paper
• The serotonergic system and cognitive function

  2016cites this paper
• Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study

  2016cites this paper
• The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases.

  2016cites this paper
• Depression and Dementia

  2016cites this paper
• Cohort Study on Meniscal Lesions among Airport Baggage Handlers

  2016cites this paper
• Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia

  2015cites this paper
• The role of serotonin 5-HT2A receptors in memory and cognition

  2015cites this paper
• Serotonin in fear conditioning processes.

  2015cites this paper
• Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer’s Disease Pathogenesis

  2015cites this paper
• The association of 5HT2A and 5HTTLPR polymorphisms with Alzheimer’s disease susceptibility: a meta-analysis with 6945 subjects

  2015cites this paper
• PET radiotracers for molecular imaging in dementia.

  2014cites this paper
• Depression in Alzheimer's Disease: Epidemiology, Mechanisms, and Management

  2014cites this paper
• Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

  2014cites this paper
• K‐Lysine acetyltransferase 2a regulates a hippocampal gene expression network linked to memory formation

  2014cites this paper
• Chronic treatment with the serotonin 2A/2C receptor antagonist SR 46349B enhances the retention and efficiency of rule-guided behavior in mice.

  2013cites this paper
• 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

  2013cites this paper
• PET Imaging of Serotoninergic Neurotransmission with [11C]DASB and [18F]altanserin after Focal Cerebral Ischemia in Rats

  2013cites this paper
• Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response.

  2013cites this paper
• A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease

  2013cites this paper
• Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice.

  2013cites this paper
• Altered serotonergic neurotransmission as a main player in the pathophysiology of Alzheimer's disease : structural and ultrastructural studies in a triple transgenic mouse model of the disease

  2012cites this paper
• The serotonergic system in ageing and Alzheimer's disease.

  2012influential citation
• Positron emission tomography in neurological and psychiatric disorders

  2012cites this paper
• Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease

  2011cites this paper
• Depression and Alzheimer's Disease: Is Stress the Initiating Factor in a Common Neuropathological Cascade?

  2011cites this paper
• Molecular Imaging in Alzheimer ’ s Disease

  2011cites this paper
• PL‐05‐03: Metabolic and molecular imaging markers throughout the course of Alzheimer's disease

  2010cites this paper